3SBio's (HKG:1530) unit Shenyang Sunshine Pharmaceutical has agreed to obtain the exclusive commercialization rights of Sunshine Lake Pharma's clifutinib besylate for specific indications in Mainland China, a Monday bourse filing said.
Under the contract, Shenyang Sunshine Pharmaceutical will pay Sunshine Lake Pharma an initial payment as well as certain R&D and sales milestone payments.
Sunshine Lake Pharma will continue to be responsible for the research and development, registration, production, and other works related to the drug.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。